JP2005518789A5 - - Google Patents

Download PDF

Info

Publication number
JP2005518789A5
JP2005518789A5 JP2003564202A JP2003564202A JP2005518789A5 JP 2005518789 A5 JP2005518789 A5 JP 2005518789A5 JP 2003564202 A JP2003564202 A JP 2003564202A JP 2003564202 A JP2003564202 A JP 2003564202A JP 2005518789 A5 JP2005518789 A5 JP 2005518789A5
Authority
JP
Japan
Prior art keywords
antibody
psma
seq
region
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003564202A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005518789A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/002448 external-priority patent/WO2003064606A2/en
Publication of JP2005518789A publication Critical patent/JP2005518789A/ja
Publication of JP2005518789A5 publication Critical patent/JP2005518789A5/ja
Pending legal-status Critical Current

Links

Images

JP2003564202A 2002-01-28 2003-01-28 前立腺特異性膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体 Pending JP2005518789A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5998902A 2002-01-28 2002-01-28
PCT/US2003/002448 WO2003064606A2 (en) 2002-01-28 2003-01-28 Human monoclonal antibodies to prostate specific membrane antigen (psma)

Publications (2)

Publication Number Publication Date
JP2005518789A JP2005518789A (ja) 2005-06-30
JP2005518789A5 true JP2005518789A5 (ko) 2006-03-02

Family

ID=27658271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003564202A Pending JP2005518789A (ja) 2002-01-28 2003-01-28 前立腺特異性膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体

Country Status (10)

Country Link
EP (1) EP1519747A4 (ko)
JP (1) JP2005518789A (ko)
KR (1) KR20040077889A (ko)
CN (1) CN1652821A (ko)
AU (1) AU2003224604B2 (ko)
BR (1) BR0307216A (ko)
CA (1) CA2474616A1 (ko)
MX (1) MXPA04007262A (ko)
NZ (1) NZ534687A (ko)
WO (1) WO2003064606A2 (ko)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105159B1 (en) 1992-11-05 2006-09-12 Sloan-Kettering Institute For Cancer Research Antibodies to prostate-specific membrane antigen
US6569432B1 (en) 1995-02-24 2003-05-27 Sloan-Kettering Institute For Cancer Research Prostate-specific membrane antigen and uses thereof
US6962981B1 (en) 1996-03-25 2005-11-08 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US7381407B1 (en) 1996-03-25 2008-06-03 Medarex, Inc. Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP2363404B8 (en) 2001-10-23 2016-12-07 PSMA Development Company L.L.C. PSMA antibodies
KR20130133302A (ko) * 2003-12-10 2013-12-06 메다렉스, 인코포레이티드 Ｉｐ―１０ 항체 및 그의 용도
DK2270045T3 (en) * 2004-02-06 2015-04-07 Univ Massachusetts ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF
EP1735348B1 (en) * 2004-03-19 2012-06-20 Imclone LLC Human anti-epidermal growth factor receptor antibody
EP2360186B1 (en) 2004-04-13 2017-08-30 F. Hoffmann-La Roche AG Anti-P-selectin antibodies
CN1997670B (zh) 2004-07-01 2014-04-30 诺和诺德公司 人类抗-kir抗体
ATE531733T1 (de) 2005-01-06 2011-11-15 Novo Nordisk As Kir-bindende wirkstoffe und verfahren zu ihrer verwendung
DK1851250T3 (da) * 2005-02-18 2012-07-09 Medarex Inc Humant monoklonalt antistof mod prostataspecifikt membranantigen (psma)
BRPI0607796A2 (pt) * 2005-02-18 2009-06-13 Medarex Inc composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
NZ563193A (en) * 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
CN101443340B (zh) * 2006-03-14 2013-12-04 癌靶技术有限责任公司 前列腺特异性膜抗原的拟肽抑制剂、含该拟肽抑制剂的化合物及用法
US8852630B2 (en) 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
PL2326350T3 (pl) 2008-09-08 2014-03-31 Psma Dev Company L L C Związki do zabijania eksprymujących PSMA, opornych na taksan komórek rakowych
SG194398A1 (en) * 2008-10-01 2013-11-29 Amgen Res Munich Gmbh Cross-species-specific psmaxcd3 bispecific single chain antibody
CN101891818B (zh) * 2009-01-16 2012-07-25 中国人民解放军第四军医大学 抗人前列腺特异性膜抗原胞外区单链抗体及其应用
US8629247B2 (en) * 2009-04-14 2014-01-14 Proscan Rx Pharma Inc. Antibodies against prostate specific membrane antigen
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
JP2014518615A (ja) 2011-04-22 2014-08-07 エマージェント プロダクト デベロップメント シアトル， エルエルシー 前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法
KR101819404B1 (ko) 2012-10-12 2018-02-28 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
CN103333249A (zh) * 2013-06-14 2013-10-02 广州康合生物科技有限公司 一种抗前列腺特异性膜抗原（psma）的单克隆抗体及其应用
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
EP3268039B1 (en) * 2015-03-10 2020-11-04 Sorrento Therapeutics, Inc. Antibody therapeutics that bind psma
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC CD3 BINDING POLYPEPTIDES
KR101704379B1 (ko) * 2015-10-27 2017-02-08 (주)알테오젠 항체-약물 접합체 및 그 제조방법
JP7328479B2 (ja) 2016-03-23 2023-08-17 ソウル大学校産学協力団 重症熱性血小板減少症候群ウイルスの外膜糖タンパク質に結合する抗体及びその用途
BR112018073761A2 (pt) 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. proteínas de ligação ao cd3 de fragmento variável de cadeia única
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
SG11201810327XA (en) 2016-05-20 2018-12-28 Harpoon Therapeutics Inc Single domain serum albumin binding protein
US20200023072A1 (en) 2016-10-11 2020-01-23 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
CA3044659A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CA3063359A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
JP7066837B2 (ja) 2017-10-13 2022-05-13 ハープーン セラピューティクス，インク． Ｂ細胞成熟抗原結合タンパク質
PT3694529T (pt) 2017-10-13 2024-09-20 Harpoon Therapeutics Inc Proteínas triespecíficas e métodos de utilização
EP3796942A1 (en) 2018-05-23 2021-03-31 ADC Therapeutics SA Molecular adjuvant
WO2020069028A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
CA3120800A1 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
TW202132353A (zh) * 2020-02-18 2021-09-01 大陸商和鉑醫藥（上海）有限責任公司 一種分離的結合抗原ｐｓｍａ的蛋白及其用途
BR112022016550A2 (pt) 2020-02-21 2022-11-16 Harpoon Therapeutics Inc Proteínas de ligação a flt3 e métodos de uso
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
US20230201366A1 (en) 2021-11-19 2023-06-29 Adc Therapeutics Sa Anti-psma conjugates
WO2024118940A1 (en) * 2022-12-01 2024-06-06 Twist Bioscience Corporation Anti-psma antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE198490T1 (de) * 1993-06-09 2001-01-15 Unilever Nv Verfahren zur herstellung von fusionsproteinen, die scfv fragmente enthalten, in transformierten schimmelpilzen
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
ES2277846T3 (es) * 1999-07-29 2007-08-01 Medarex, Inc. Anticuerpos monoclonales humanos para antigeno prostatico especifico.
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
KR101155294B1 (ko) * 2000-06-16 2013-03-07 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
EP2363404B8 (en) * 2001-10-23 2016-12-07 PSMA Development Company L.L.C. PSMA antibodies
AU2003270010A1 (en) * 2002-08-30 2004-03-19 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
AU2003298799A1 (en) * 2002-12-02 2004-06-23 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof

Similar Documents

Publication Publication Date Title
JP2005518789A5 (ko)
JP7412521B2 (ja) Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体
BR112021010402A2 (pt) Anticorpos biespecíficos anti-pd-l1/anti-4-1bb e uso dos mesmos
JP2018521691A (ja) 増殖性および炎症性疾患の処置における抗ＴｆＲ抗体およびその使用
KR20200070324A (ko) 항-cd71 활성화 가능한 항체 약물 접합체 및 이의 사용 방법
WO2021197359A1 (zh) 一种构建多特异性抗体的平台
CN109721656B (zh) 靶向rankl的治疗性抗体
US20210284715A1 (en) Coagulation factor viii mimetic protein and uses thereof
JP7357012B2 (ja) 抗ｂｃｍａ ｃａｒ抗体、コンジュゲート、および使用方法
JP2021518748A (ja) カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）アンタゴニスト抗体
JP2023506262A (ja) 抗ｂｃｍａ ｃａｒ抗体、コンジュゲートおよび使用方法
WO2023207475A1 (zh) 靶向gpc3的单克隆抗体和包含此抗体的抗体药物缀合物
CN111742220A (zh) 检测癌症患者中的肿瘤抗原的诊断性测定法
US10584175B2 (en) FN14-binding proteins and uses thereof
CN111108120A (zh) 抗人类血管内皮生长因子受体的抗体及其应用
CN113166264B (zh) 一种分离的抗原结合蛋白及其用途
CN115850458A (zh) 一种抗冠状病毒rbd蛋白的抗体、制备方法和应用
CA3227486A1 (en) Deimmunized vnar domains and scaffolds
JP2022540904A (ja) ヒトｔｒｅｍ－１に対する抗体およびその使用
WO2017125601A1 (en) Anti-bsep-specific antibodies